Long-term benefits from targeted therapy for GIST
George Demetri, MD, Senior Vice President for Experimental Therapeutics at Dana-Farber Cancer Institute, discusses the lasting benefit of targeted therapy that included Gleevec in advanced GIST at the recent 50th Annual Meeting of the American Society [...]